CN Patent

CN117180235A — 一种无定型雷芬那辛吸入制剂

Assigned to Jewim Pharmaceutical Shandong Co ltd · Expires 2023-12-08 · 2y expired

What this patent protects

本发明公开了一种雷芬那辛无定型晶型的吸入制剂。本发明所述雷芬那辛无定型晶型制成的吸入制剂具有稳定性好，在体内有效部位沉积占比高，疗效好，副作用低的优点，为COPD患者的治疗提供新的药物选择。

USPTO Abstract

本发明公开了一种雷芬那辛无定型晶型的吸入制剂。本发明所述雷芬那辛无定型晶型制成的吸入制剂具有稳定性好，在体内有效部位沉积占比高，疗效好，副作用低的优点，为COPD患者的治疗提供新的药物选择。

Drugs covered by this patent

Patent Metadata

Patent number
CN117180235A
Jurisdiction
CN
Classification
—
Expires
2023-12-08
Drug substance claim
No
Drug product claim
No
Assignee
Jewim Pharmaceutical Shandong Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.